PARADIGM is the first prospective trial to examine panitumumab versus bevacizumab in colorectal cancer. Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the findings of the phase III PARADIGM study in patients with RAS wild-type (WT) metastatic colorectal cancer.
The abstract entitled ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial’ (Abstract number LBA10) was presented at the ASCO annual meeting, June 3-7, 2022.
Disclosures: Benjamin Weinberg has received grant/research support from Ipsen, is on the advisory board for Bayer and Taiho and the speaker’s bureau for AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Sirtex and Taiho.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
